Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: Results from a randomized controlled trial

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 5, 2007, Pages 555-563

  Maru, Duncan Smith Rohrberg ^a   Kozal, Michael J ^a   Bruce, R Douglas ^a   Springer, Sandra A ^a   Altice, Frederick L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adherence; Directly administered antiretroviral therapy; Directly observed therapy; HIV genotypic resistance substance use disorders; HIV AIDS

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SELF ADMINISTRATION; DRUG USE; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; VIRUS RESISTANCE;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SELF ADMINISTRATION; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 36549060651     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318158c0bd     Document Type: Article

References (51)

1. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
2. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
3. Kozal MJ, Amico KR, Chiarella J, et al. HIV drug resistance and HIV transmission risk behaviors among active injection drug users. J Acquir Immune Defic Syndr. 2005;40:106-109.
4. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
5. Antela A. Access to antiretroviral therapy in HIV-infected injection drug users. AIDS. 2001;15:1727-1728.
6. Strathdee SA, Palepu A, Cornelisse PG, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-549.
7. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15:1707-1715.
8. Ding L, Landon BE, Wilson IB, et al. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med. 2005;165:618-623.
9. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774.
10. Lucas GM, Griswold M, Gebo KA, et al. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol. 2006;163:412-420.
11. Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis. 2004;38(Suppl 5):S402-S408.
12. Lucas GM, Weidle PJ, Hader S, et al. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis. 2004;38(Suppl 5):S409-S413.
13. Mitty JA, Macalino GE, Bazerman LB, et al. The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. J Acquir Immune Defic Syndr. 2005;39:545-550.
14. Behforouz HL, Kalmus A, Scherz CS, et al. Directly observed therapy for HIV antiretroviral therapy in an urban US setting. J Acquir Immune Defic Syndr. 2004;36:642-645.
15. Tinoco I, Giron-Gonzalez JA, Gonzalez-Gonzalez MT, et al. Efficacy of directly observed treatment of HIV infection: experience in AIDS welfare homes. Eur J Clin Microbiol Infect Dis. 2004;23:331-335.
16. Greenberg B, Berkman A, Thomas R, et al. Evaluating supervised HAART in late-stage HIV among drug users: a preliminary report. J Urban Health. 1999;76:468-480.
17. Wohl DA, Shain L, Adamian M, et al. HIV transmission risk behaviors among HIV-infected individuals released from prison. Presented at: 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston.
18. Altice FL, Maru DS, Bruce RD, et al. Superiority of directly administered antiretroviral therapy compared to self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis. 2007;45:770-778.
19. Macias J, Palomares JC, Mira JA, et al. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J Infect. 2005;51:195-200.
20. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother. 2004;53:696-699.
21. Friedland GH, Williams A. Attaining higher goals in HIV treatment: the central importance of adherence. AIDS. 1999;13(Suppl 1):S61-S72.
22. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS. 2003;17:1925-1932.
23. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003;37:1112-1118.
24. Wood E, Hogg RS, Yip B, et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 X 10(9) cells/L. Ann Intern Med. 2003;139:810-816.
25. Bangsberg DR, Porco TC, Kagay C, et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis. 2004;190:162-165.
26. Altice FL, Mezger JA, Hodges J, et al. Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication. Clin Infect Dis. 2004;38(Suppl 5):S376-S387.
27. Smith-Rohrberg D, Mezger J, Walton M, et al. Impact of enhanced services on virological outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S48-S53.
28. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255-266.
29. Amico KR, Fisher WA, Cornman DH, et al. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr. 2006;42:455-459.
30. Giordano TP, Guzman D, Clark R, et al. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5:74-79.
31. Gross R, Yip B, Re VL 3rd, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108-1114.
32. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
33. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
34. Smith-Rohrberg D, Altice FL. Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: questions about study population and analytical approach. Clin Infect Dis. 2006;43:1221-1222.
35. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194(Suppl 1):S51-S58.
36. Hales G, Birch C, Crowe S, et al. A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST Study. PLoS Clin Trials. 2006;1:e18.
37. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med. 2006;14:125-130.
38. Jiang H, Deeks SG, Kuritzkes DR, et al. Assessing resistance costs of antiretroviral therapies via measures of future drug options. J Infect Dis. 2003;188:1001-1008.
39. Kantor R, Machekano R, Gonzales MJ, et al. Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res. 2001;29:296-299.
40. Rodes B, Garcia F, Gutierrez C, et al. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral- experienced HIV-infected patients. J Med Virol. 2005;77:23-28.
41. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 2001;286:196-207.
42. Hatano H, Hunt P, Weidler J, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis. 2006;43:1329-1336.
43. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 2001;344:472-480.
44. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793.
45. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-706.
46. Harrigan PR, Wynhoven B, Brumme ZL, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis. 2005;191:1325-1330.
47. Johnson J, Li JF, Wei X, et al. Low-frequency mutations substantially increase the prevalence of transmitted drug resistance and greatly strengthen the relationship between resistance mutations and virologic failure. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; 2007; Los Angeles.
48. Simen B, Huppler K, Hullsiek T, et al. Prevalence of low abundant drug resistant variants by ultra-deep sequencing in chronically HIV-infected antiretroviral (ARV) naive patients and the impact on virologic outcomes. Presented at: XVI International HIV Drug Resistance Workshop; 2007;Bridgetown, Barbados.
49. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357-366.
50. Liechty CA, Bangsberg DR. Doubts about DOT: antiretroviral therapy for resource-poor countries. AIDS. 2003;17:1383-1387.
51. Kushel MB, Colfax G, Ragland K, et al. Case management is associated with improved antiretroviral adherence and CD4+ cell counts in homeless and marginally housed individuals with HIV infection. Clin Infect Dis. 2006;43:234-242.